Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies - GBI Research Reports

Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies

Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies - GBI Research Reports
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
Published Nov 07, 2011
68 pages — Published Nov 07, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in 12 European nations with a detailed analysis of the different regulatory mechanisms used in these countries. The report closely scrutinizes the major changes in the pharmaceuticals related pricing and reimbursement in these European nations in the recent past and their impact in the near future. The countries analyzed in the report are the top five countries of Europe, Eastern European countries such as Czech Republic, Poland, Romania and Hungary as well as Scandinavian countries such as Norway, Finland and Denmark.

GBI Researchs analysis describes healthcare across the 12 European nations, which is largely publicly financed and is provided by health insurance systems; hence, the European governments play a key role in providing healthcare for their citizens. Health is of high priority for Europes citizens and pharmaceutical costs are the third most important component in the member states healthcare budgets. Currently, the governments of the member countries face substantially rising costs for the provision of health care (average costs are rising at a faster rate than GDP) due to over-prescription of drugs, their irrational usage, and other key factors such as Europes ageing population and increasing cost of new medical technologies. Consumer preference for branded drugs to generic drugs in cases where the patent for the drug has expired is also one of the reasons for increasing healthcare costs. Austerity packages announced by the countries are incorporating demand side and supply side policies to reduce the fiscal burden of which healthcare costs command a major proportion. The governmental demand side policies include measures that affect the reimbursements of drugs such as positive and negative lists, cost sharing, reference pricing, risk-sharing contracts, tenders, pay-back arrangements and other provisions aimed at a more rational use of pharmaceutical products and making demand more price sensitive. The most applied supply policy is price regulation which includes price control and price negotiation. The specific features of individual policies vary significantly across the member states. Single pricing mechanism is still an issue in the Europe.

Scope

- Detailed study of the healthcare systems and roles of the key players in the respective pharmaceutical systems of top five countries of Europe the UK, France, Germany, Italy and Spain; Eastern European countries of Czech Republic, Poland, Hungary, and Romania; and Scandinavian countries of Norway, Denmark and Finland.
- Analysis of the major pricing and reimbursement mechanisms in each country.
- Key trends that follow from the recent changes brought about in the pricing and reimbursement mechanism.
- Build an understanding of the possible major challenges brought about by the enactment of changes in the pricing and reimbursement scene in the countries covered.

Reasons to buy

- Build understanding of the pharmaceuticals related key pricing and reimbursement mechanisms in the key markets of Europe.
- Optimize your investment through identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the economies.
- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in pricing and reimbursement scene for the countries covered.

  
Source:
Document ID
GBIHC122MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents43
  List of Tables61
  List of Figures61
Pricing and Reimbursement in Europe - Introduction71
  GBI Research Report Guidance71
Pricing and Reimbursement in Europe - Overview816
  Healthcare Expenditure Highly Correlated with GDP102
  Relation between Pharmaceutical Expenditure and GDP121
  Overview of Pharmaceutical Regulations in Europe131
    Negotiations141
    International Price Referencing141
    Internal Reference Pricing151
    Tendering151
    Price Capping of Generic Pharmaceuticals151
    Use of Positive and Negative Formulary161
    Value Based Pricing and Risk-Sharing Models162
    Increased Focus on Evidence-based Medicine and Health Technology Assessment (HTA)181
    Role of Pharmacoeconomics in Pricing and Reimbursement191
    EU Single Pricing Still an Unresolved Issue201
  Recent Major Changes in Pricing and Reimbursement of Drugs in Europe211
    The UK to Adopt VBP Replacing PPRS from 2014 despite Concerns of Companies and Experts Alike211
    Major Challenge Regarding VBP Adoption in the UK211
    France Decreases Reimbursement for Drugs with Moderate Clinical Benefits Along With Overall Price Cuts211
    Benefit Assessment Led Price Negotiation, Price Freeze and Mandatory Discounts Key Features Of German P&R Changes221
    Italian P&R Scene Dominated By Price Cuts and Changes in Reference Price Level221
    Main Austerity Measures in Spain Include 7.5% Rebate for In-Patent Drugs and Price Cuts for Generics221
    Renewed P&R Cut Of 7% in Czech Republic and Proposed Changes in VAT for 2012 And 2013221
    Expenditure on Reimbursement of Medicines Fixed At 17% of the NHF in Poland231
    Levy on Sale of Reimbursed Drugs in Hungary to Go Up To 20%; Payment-By-Result another Major Move231
Pricing and Reimbursement in Europe - The Top Five Countries of Europe2427
  The UK251
    Healthcare System in the UK251
    Healthcare expenditure Other Developed Countries More Prominent Healthcare Spenders261
    Pricing and Reimbursement Process in the UK272
    Key Trends291
      Changeover to the New PPRS in 2009 Key Points291
      Value-Based Pricing In The Future301
    Major Challenges301
  France311
    Healthcare System in France312
    Pricing and Reimbursement Process in France331
      Important Players331
      Financing Law of Social Security (LFSS) 2011342
    Key Trends361
      Pharmaceutical Price Cuts Including Parallel Import Drugs361
      CEPS Adjustments to Drug Pricing Methods361
      Generics Substitution Missed Targets in 2010371
      CEPS Imposes Reference Prices for Branded Antihypertensive From 2011371
      Reimbursement Restrictions for Drugs of Limited Clinical Merit Rating381
      Exclusion of Benign Hypertension from Reimbursement381
      Reimbursement Cuts for Drugs with Moderate Clinical Benefit and Medical Devices381
      Swift End to Reimbursement of Drugs That Offer Minimal Clinical Benefit391
    Major Challenges391
  Germany401
    Healthcare System in Germany401
    Pricing and Reimbursement Process in Germany411
    Key Trends421
      Cost-Containing Measures According To the AMNOG For Patented Drugs431
      Impact of Pricing Reform Pharmaceutical Manufacturers No Longer Able To Fix Prices441
      Expansion of the Reference-Pricing System441
      16% Rebate on Non-Reference Drug Sales Further Cost Containment441
      Rebate Contracts between Health Insurance Funds and Manufacturers of Generics441
      Reimbursement Prices441
    Major Challenges451
  Italy451
    Healthcare System in Italy451
    Pricing and Reimbursement Process in Italy451
    Key Trends461
      Off-Patent Drugs and Generics Prices Targeted By Lowering Their Reference Prices461
      Margin Cuts Of Wholesaler and Pharmacists On Top Of Price Limits461
      New List of Innovative Drugs that Regions Obligated to Reimburse Provide Incentive for Pharmaceutical Companies462
    Major Challenges481
      Impact on Profitability of Branded Drugs by Innovator Companies due to Prescription of Cheapest Version of a Drug481
      Challenge for Generics Producers481
  Spain481
    Healthcare System in Spain481
    Pricing and Reimbursement Process in Spain481
    Key Trends491
      Change in the Reference Pricing System491
      Drugs Marketed For Over 10 Years to Have Increased Price Reduction491
      Rebates Imposed On Patented and Orphan Medicines491
      Average Price Cut of 25% on Generic Drugs491
      Further Pricing Pressure Due To Tendering System and Other Demand-Side Initiatives by Regional Authorities501
    Major Challenges501
Pricing and Reimbursement in Europe - Eastern Europe5110
  Czech Republic521
    Healthcare System in Czech Republic521
    Pricing and Reimbursement Process in the Czech Republic521
    Key Trends531
      Reduction By 7% of Drug Prices for Drugs Not Reviewed By SUKL Valid For One More Year531
      Changes in VAT on Medicines Expected From 2012531
    Major Challenges531
  Poland531
    Healthcare System in Poland531
    Pricing and Reimbursement Process in Poland541
    Key Trends541
      Removal of the Proposed 3% Reimbursement in the Initial Draft of Reimbursement Act541
      Expenditure on Reimbursement of Medicines Fixed At 17% of the Total Annual Budget of Polish NHF Could Spell Well For Innovators551
      Fixed Price on Reimbursed Medicines to Hurt Profitability551
      Margins of Wholesalers to Be Reduced Gradually551
      Risk-sharing Agreements for Costly Innovative Drugs551
      Extension of Reference Pricing For High-Cost Drugs in Hospitals May Affect Prices561
    Major Challenges561
  Romania561
    Pricing and Reimbursement Process in Romania561
    Key Trends571
      New International Reference Pricing Will Give a Boost to Generics Producers571
      Change in Reference Price Calculation to Affect High-Cost Drugs Revenue and Increase Co-Payment for Patients571
    Major Challenges581
  Hungary581
    Healthcare System in Hungary581
    Pricing and Reimbursement Process in Hungary581
    Key Trends591
      Price Fixing Of Composite Drugs to Deliver Savings591
      Increase in Levy on Revenues from Reimbursed Drugs Sale from 12% to 20%591
      Payment-by-Results to Be Introduced As Part of the Structural Reform Measures601
      Generics Set for Further 5% Reference Price Reductions601
    Major Challenges601
Pricing and Reimbursement in Europe - Scandinavia613
  Norway621
  Finland621
  Denmark622
Pricing and Reimbursement in Europe - Appendix645
  Market Definitions641
  Abbreviations642
  Research Methodology662
    Healthcare System661
    Pricing and Reimbursement Process671
    Key Trends671
    Major Challenges671
  Contact Us671
  Disclaimer671
  Sources681

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies" Nov 07, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pharmaceutical-Pricing-and-Reimbursement-in-Europe-Reference-Pricing-and-Similar-Initiatives-Being-Applied-to-Innovative-Drugs-Pose-Significant-Challenge-to-Pharmaceutical-Companies-2115-295>
  
APA:
GBI Research Reports. (2011). Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies Nov 07, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pharmaceutical-Pricing-and-Reimbursement-in-Europe-Reference-Pricing-and-Similar-Initiatives-Being-Applied-to-Innovative-Drugs-Pose-Significant-Challenge-to-Pharmaceutical-Companies-2115-295>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.